-- Mary Elizabeth Dallas
FRIDAY, Feb. 28, 2014 (HealthDay News) -- Black Americans
respond better to the rubella vaccine, which prevents German
measles, than whites or Hispanics, according to a new study.
Researchers said their findings could lead to more effective
vaccines that target specific groups or individuals.
"We don't know why these groups reacted so differently to the vaccine -- that's a subject for further studies -- but this new information will help us as we design the vaccines of the future," said the study's senior author, Dr. Gregory Poland, a vaccinologist with the Mayo Clinic in Rochester, Minn. "It will ultimately change how we practice medicine."
The study, published Feb. 26 in the journal
Vaccine, involved 1,100 healthy children and young adults in
Rochester, Minn., as well as 1,000 recently vaccinated members of
the U.S. Navy who acted as a control group.
After receiving the current rubella vaccine, Somali Americans
developed twice as many antibodies to the virus as white people,
the researchers found. Another group of non-Somali blacks had the
second highest immune response to the vaccine, which was still
significantly better than whites. Meanwhile, Hispanic Americans had
the lowest immune response to the rubella vaccine.
"The significance of the findings is that in the future we may be able to create vaccines for specific groups or even individuals based on their genomic and other characteristics," Poland noted in a Mayo news release. "That may mean adjusting doses for some or being able to treat larger populations with the same vaccine if the dosage is less."
Although previous studies have suggested that women have a
better response to vaccines than men, this study did not find that
sex contributed to differences in the participants' immune
Poland is the chair of a safety evaluation committee for
non-rubella vaccine trials being conducted by Merck Research
Laboratories. He also holds two patents related to vaccinia peptide
research and advises major pharmaceutical companies, including
Merck, Sanofi Pasteur, Dynavax, Novartis Vaccines and Therapeutics,
and Emergent BioSolutions, on vaccine development.
The rubella vaccine is usually given as part of the MMR vaccine
(protecting against measles, mumps and rubella). MMR is recommended
at 12 to 15 months of age followed by a second dose when the child
is 4 to 6 years old.
The virus causes a rash for about three days.
The U.S. Centers for Disease Control and Prevention provides
more information on the
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.